Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis

Control of cutaneous leishmaniasis (CL) in the Americas is dependent on chemotherapy with parenteral pentavalent antimonials. High rates of treatment failure urge the search for predictive and prognostic markers of therapeutic responsiveness. In this study, we aimed to identify biomarkers of therape...

Full description

Bibliographic Details
Main Authors: Deninson Alejandro Vargas, Miguel Dario Prieto, Alvaro José Martínez-Valencia, Alexandra Cossio, Karl E. V. Burgess, Richard J.S. Burchmore, María Adelaida Gómez
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Pharmacology
Subjects:
cutaneous leishmaniasis
meglumine antimoniate
pharmacometabolomics
biomarkers
allantoin
taurine
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00657/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00657/full

Similar Items